Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pediatric acute lymphoblastic leukemia.

William L Carroll1, Deepa Bhojwani, Dong-Joon Min

  • 1Mount Sinai and New York University Schools of Medicine, New York, NY 10029-6574, USA.

Hematology. American Society of Hematology. Education Program
|November 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report.

Blood neoplasia·2026
Same author

Integrin alpha 4 inhibition prolongs the survival of NSG mice engrafted with CD19-negative post-CART19 relapsed B-ALL.

Experimental hematology·2026
Same author

A Model for Clinician and Staff Education in the Engagement of American Indians in Genomic Research.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

A Multiregional Decentralized Clinical Trial Program to Improve Access.

JAMA network open·2026
Same author

Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemia.

Leukemia·2026
Same author

Reduced-intensity reinduction for children and young persons with relapsed acute lymphoblastic leukemia.

Leukemia·2026
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Improving outcomes for acute lymphoblastic leukemia (ALL) requires better risk prediction. Gene expression profiling and host genetic variations offer new ways to classify ALL and personalize treatment for better survival.

Area of Science:

  • Pediatric Oncology
  • Molecular Biology
  • Genetics

Background:

  • Outcomes for childhood acute lymphoblastic leukemia (ALL) have improved, but 25% of patients still fail therapy.
  • Better methods are needed to predict treatment response and identify patients requiring intensified therapy.
  • Novel treatments targeting the leukemic process are urgently required.

Purpose of the Study:

  • To review current and emerging strategies for classifying acute lymphoblastic leukemia (ALL).
  • To explore the role of genetic variations and gene expression profiling in predicting ALL outcomes.
  • To discuss novel therapeutic approaches targeting apoptotic pathways in ALL.

Main Methods:

  • Review of clinical parameters, genetic lesions, and early response in ALL risk classification.

Related Experiment Videos

  • Analysis of host germline variations and polymorphisms in drug-metabolizing genes (e.g., TPMT).
  • Application of gene expression profiling to classify ALL subtypes and identify outcome-predictive genes.
  • Examination of apoptotic pathways and key protein expression (e.g., BCL2, BAX, caspase 3).

    • Main Results:

    • Incorporation of clinical, genetic, and early response parameters can improve ALL risk classification.
    • Germline variations, such as TPMT polymorphisms, influence drug toxicity and patient outcomes.
    • Gene expression profiling identified novel ALL subtypes and potential outcome-predictive gene signatures.
    • Apoptotic pathway modulation presents a promising avenue for novel ALL therapeutic strategies.

    Conclusions:

    • Advanced classification systems integrating genomics and proteomics are essential for personalized ALL treatment.
    • Understanding host genetic factors and gene expression patterns can optimize therapy selection.
    • Targeting apoptosis pathways offers new therapeutic opportunities for refractory or relapsed ALL.
    • Further validation is needed to integrate novel biomarkers into clinical decision-making for ALL.